The IL-6 (with IL-6 being downstream IL-1) antagonist, tocilizumab, which blocks soluble and membrane‐bound IL‐6R, exerts beneficial effects in a high‐risk population (rheumatoid arthritis patients), even as it increases total cholesterol and low‐density lipoprotein levels (62). Here, IL6 is linked to rheumatoid arthritis.